Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163319
Status:
COMPLETED
Last Update Posted:
2016-12-02
First Post:
2005-09-12
Brief Title:
Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma 18 to 75 y BY9010IT-101
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Comparison of Inhaled Ciclesonide 640 mcgDay and Fluticasone Propionate 1000 mcgDay in Patients With Moderate and Severe Persistent Asthma
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to compare the safety and efficacy of ciclesonide versus fluticasone propionate on the lung function symptoms use of rescue medication and occurrence of side effects such as candidiasis hoarseness in adults with persistent asthma Ciclesonide will be inhaled twice daily at one dose level fluticasone propionate will be inhaled twice daily at one dose level The study duration consists of a baseline period 2 weeks and a treatment period 24 weeks The study will provide further data on safety and tolerability of ciclesonide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None